Background: The prevalence of metabolic syndrome increased by 35% in the United States starting in the 1980s, according to the Centers for Disease Control and Prevention (CDC). Changes in the structure and function of the kidneys have been related to metabolic syndrome. Reduced eGFR (estimated glomerular filtration rate) and proteinuria risk have been linked to metabolic syndrome and its various components. Moreover, numerous investigations revealed a correlation between reduced eGFR and metabolic syndrome. The aim: This study aims to investigate metabolic syndrome as a risk factor for the development of kidney dysfunction. Methods: By comparing itself to the standards set by the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020, this study was able to show that it met all of the requirements. So, the experts were able to make sure that the study was as up-to-date as it was possible to be. For this search approach, publications that came out between 2014 and 2024 were taken into account. Several different online reference sources, like Pubmed and ScienceDirect, were used to do this. It was decided not to take into account review pieces, works that had already been published, or works that were only half done. Results: In the PubMed database, the results of our search brought up 80 articles, whereas the results of our search on ScienceDirect brought up 164 articles. The results of the search conducted by title screening yielded a total of 17 articles for PubMed and 23 articles for ScienceDirect. We compiled a total of 20 papers, 14 of which came from PubMed and 6 of which came from ScienceDirect. We excluded 1 review article, 1 non-full text article, 1 article having insufficient outcomes, and 2 articles having ineligible subjects. In the end, we included fifteen research that met the criteria. Conclusion: Metabolic syndrome is a risk factor for the development of kidney dysfunction. Metabolic syndrome increases the incidences of CKD and proteinuria and decreases GFR. These findings suggest that it is important to screen for CKD in patients with metabolic syndrome.